Belite Bio Inc Quick Ratio (BLTE) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Belite Bio Inc  (BLTE)

Belite Bio Inc's Quick Ratio

BLTE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 36.61 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Quick Ratio than Belite Bio Inc in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 71, from total ranking in the third quarter 2025 at 300.

Explain Quick Ratio?
How much Cash & cash equivalents BLTE´s has?
What are BLTE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BLTE Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 66.97 % 66.97 % 66.97 % 66.97 % 58.93 %
Y / Y Cash & cash equivalent Change 874.25 % 874.25 % 874.25 % 874.25 % -58.91 %
Quick Ratio MRQ 36.61 36.61 36.61 36.61 6.27
BLTE's Total Ranking # 71 # 300 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % 66.97 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 874.25 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 15
Overall Market # 71


Quick Ratio Statistics
High Average Low
36.61 21.79 6.27
(Dec 31 2025)   (Dec 31 2024)




Financial Statements
Belite Bio Inc's Current Liabilities $ 10 Millions Visit BLTE's Balance sheet
Belite Bio Inc's Cash & cash equivalent $ 353 Millions Visit BLTE's Balance sheet
Source of BLTE's Sales Visit BLTE's Sales by Geography


Cumulative Belite Bio Inc's Quick Ratio

BLTE's Quick Ratio for the trailling 12 Months

BLTE Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 66.97 % 65.58 % 63.87 % 61.72 % 58.93 %
Y / Y Cash & cash equivalent TTM Growth 874.25 % 456.31 % 212.87 % 53.51 % -58.91 %
Quick Ratio TTM 36.61 31.56 25.25 17.12 6.27
Total Ranking TTM # 2054 # 3356 # # #
Seq. Current Liabilities TTM Growth 11.15 % 12.54 % 14.34 % 16.74 % 10.22 %
Seq. Cash & cash equivalent TTM Growth 28.92 % 40.69 % 68.61 % 218.56 % -26.38 %

Quick ratio ranking by company, industry and sector >> Back to BLTE Financial Strength Comparisons >> Go to Compare BLTE Quick Ratio to its Competitors

On the trailing twelve months basis BLTE Cash & cash equivalent more than doubled by 874.25 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Belite Bio Inc's Quick Ratio to 36.61, above BLTE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 367 other companies have achieved higher Quick Ratio than Belite Bio Inc. While Quick Ratio overall ranking has improved so far to 2054, from total ranking during the twelve months ending third quarter 2025 at 3356.

Explain Quick Ratio?
How much Cash & cash equivalents BLTE´s has?
What are BLTE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 368
Healthcare Sector # 699
Within the Market # 2054


trailing twelve months Quick Ratio Statistics
High Average Low
35.71 20 5.99
(Dec 31 2025)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Altimmune inc   100.65 $ 273.456  Millions$ 2.717  Millions
Pasithea Therapeutics Corp   97.62 $ 110.419  Millions$ 1.131  Millions
Benitec Biopharma Inc   67.54 $ 97.799  Millions$ 1.448  Millions
Gh Research Plc  65.27 $ 246.251  Millions$ 3.773  Millions
Terns Pharmaceuticals Inc   62.09 $ 1,018.982  Millions$ 16.411  Millions
Spruce Biosciences Inc   51.86 $ 48.906  Millions$ 0.943  Millions
Liquidia Corporation  51.84 $ 190.680  Millions$ 3.678  Millions
Incannex Healthcare Inc  44.54 $ 68.900  Millions$ 1.547  Millions
Emmis Acquisition Corp   43.67 $ 0.948  Millions$ 0.022  Millions
Janux Therapeutics Inc   38.67 $ 966.567  Millions$ 24.997  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Curanex Pharmaceuticals Inc  36.30 $ 4.973  Millions$ 0.137  Millions
Prothena Corporation Public Limited Company  36.01 $ 307.531  Millions$ 8.539  Millions
Minerva Neurosciences Inc   35.93 $ 82.302  Millions$ 2.290  Millions
Ligand Pharmaceuticals Incorporated  33.03 $ 1,236.811  Millions$ 37.447  Millions
Roivant Sciences Ltd   32.71 $ 4,886.891  Millions$ 149.411  Millions
Disc Medicine Inc   32.19 $ 791.152  Millions$ 24.579  Millions
Fulcrum Therapeutics Inc   27.00 $ 352.306  Millions$ 13.048  Millions
Contineum Therapeutics Inc   26.98 $ 262.896  Millions$ 9.744  Millions
Rapport Therapeutics Inc   25.75 $ 490.539  Millions$ 19.049  Millions
Upstream Bio Inc   25.39 $ 341.509  Millions$ 13.452  Millions
Mbx Biosciences Inc   24.12 $ 373.705  Millions$ 15.495  Millions
Structure Therapeutics Inc   22.85 $ 1,446.197  Millions$ 63.285  Millions
Monopar Therapeutics Inc   22.61 $ 61.834  Millions$ 2.735  Millions
Kairos Pharma Ltd   22.57 $ 4.491  Millions$ 0.199  Millions
Sagimet Biosciences inc   22.52 $ 113.124  Millions$ 5.023  Millions
Dyne Therapeutics Inc   21.94 $ 1,110.562  Millions$ 50.625  Millions
Arca Biopharma Inc  21.92 $ 337.044  Millions$ 15.374  Millions
Aprea Therapeutics Inc   20.46 $ 14.599  Millions$ 0.714  Millions
Spyre Therapeutics Inc   20.40 $ 1,197.428  Millions$ 58.685  Millions

Date modified: 2026-07-07T09:35:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.